6L9.F ViewRay €0.025 XETRA after hours 09 Apr 2026: High-volume spike alert

6L9.F stock jumped to €0.025 on XETRA after hours on 09 Apr 2026, a 2400.00% intraday change from the prior close on heavy activity. The move came with 3,500.00 shares traded, a relative volume near 12.54x the average, making ViewRay, Inc. one of today’s high-volume movers on the Germany market. We break down the trade, the company fundamentals, and what this spike means for short-term traders and longer-term holders.

Market move: 6L9.F stock after-hours performance

The headline fact is a jump to €0.025 from the previous close of €0.001, recorded in after-hours trading on XETRA on 09 Apr 2026. That represents a reported intraday change of €0.024 and 2400.00% in quoted change percentage. Given the low base, the absolute move is small in value but large in percentage terms, which increases headline volatility and trading interest.

Volume and liquidity: why 6L9.F stock flagged as a high-volume mover

Volume was 3,500.00 vs an average volume of 279.00, giving a relative volume of 12.54. For XETRA-listed ViewRay, Inc., that volume spike matters because shares outstanding are 8,289,130,240.00, and typical daily liquidity is thin. High relative volume on a sub-euro price often reflects concentrated trades, news flow, or block orders rather than broad retail demand.

Fundamentals and valuation: where 6L9.F stock stands

ViewRay, Inc. (6L9.F) shows trailing EPS of -0.55 and a negative PE around -0.05, reflecting losses. Market cap on XETRA is roughly €207,228,256.00. Key ratios: price-to-sales 2.36, price-to-book 0.06, current ratio 2.36, and debt-to-equity 1.05. Compared with the Germany healthcare sector average price-to-sales near 3.40, ViewRay trades at a discount on book value but carries negative profitability and cash flow metrics.

Catalysts and risk factors affecting 6L9.F stock

Primary upside catalysts include renewed clinical adoption of MRIdian systems and contract announcements in Europe or Asia. Risks include persistent operating losses, long days-sales-outstanding (147.79) and concentrated device replacement cycles. With year high €4.60 and year low €0.0005, price history shows extreme volatility and the stock is sensitive to single announcements.

Meyka AI rates 6L9.F with a score out of 100 and technicals

Meyka AI rates 6L9.F with a score out of 100: 57.66 (Grade C+, Suggestion: HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Technically, the 50-day average is €0.31916 and 200-day average is €2.71739, indicating the after-hours spike remains far below trend averages.

Analyst outlook and price targets for 6L9.F stock

Public consensus price targets are not available for 6L9.F on XETRA. Meyka AI’s model projects a 12-month scenario price of €0.10, implying +300.00% vs the current €0.025; an alternate conservative scenario gives €0.02, implying -20.00% downside. Forecasts are model-based projections and not guarantees. Traders should treat targets as scenario-based guides, not certainties.

Final Thoughts

Key takeaways for 6L9.F stock on XETRA after hours 09 Apr 2026: the price moved to €0.025 on a 2400.00% quoted change with 3,500.00 shares traded, flagging a high-volume event in a thinly traded name. Fundamentals show negative EPS -0.55, a low price-to-book 0.06, and sizeable shares outstanding 8,289,130,240.00, which together mean headline gains can reverse quickly. Meyka AI’s forecast model projects a 12-month target of €0.10, implying +300.00% from current levels, but this is model-based and not a guarantee. Given the company’s cash per share €0.75 and a debt-to-equity of 1.05, investors should weigh liquidity and execution risk before positioning. For live updates visit ViewRay’s site and the Meyka stock page for real-time signals and AI-powered market analysis.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.